A subset of IL-17 + mesenchymal stem cells possesses anti- Candida albicans effect

Ruili Yang,Yi Liu,Peyman Kelk,Cunye Qu,Kentaro Akiyama,Chider Chen,Ikiru Atsuta,WanJun Chen,Yanheng Zhou,Songtao Shi

DOI: https://doi.org/10.1038/cr.2012.179

IF: 44.1

2012-01-01

Cell Research

Abstract:Bone marrow mesenchymal stem cells (MSCs) comprise a heterogeneous population of postnatal progenitor cells with profound immunomodulatory properties, such as upregulation of Foxp3 + regulatory T cells (Tregs) and downregulation of Th17 cells. However, it is unknown whether different MSC subpopulations possess the same range of immunomodulatory function. Here, we show that a subset of single colony-derived MSCs producing IL-17 is different from bulk MSC population in that it cannot upregulate Tregs, downregulate Th17 cells, or ameliorate disease phenotypes in a colitis mouse model. Mechanistically, we reveal that IL-17, produced by these MSCs, activates the NFκB pathway to downregulate TGF-β production in MSCs, resulting in abolishment of MSC-based immunomodulation. Furthermore, we show that NFκB is able to directly bind to TGF-β promoter region to regulate TGF-β expression in MSCs. Moreover, these IL-17 + MSCs possess anti- Candida albicans growth effects in vitro and therapeutic effect in C. albicans -infected mice. In summary, this study shows that MSCs contain an IL-17 + subset capable of inhibiting C. albicans growth, but attenuating MSC-based immunosuppression via NFκB-mediated downregulation of TGF-β.